AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02830243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
Study NCT00839566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: AV-node ablation
Study NCT00839566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Rate control by drug
Study NCT01537315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
Study NCT01537315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT02255617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal transplant processed from routinely screened universal donors
Study NCT00742625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00067821 — intervention group
Intervention type: DRUG
Intervention: 2-Flourodeoxyglucose
Study NCT00742625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00742625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01306643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablet(s) administered orally twice daily
Study NCT03218839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex male circumcision device
Description: PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
Study NCT00129285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Modafinil
Description: modafinil 200 mg/day
Study NCT00129285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Modafinil
Description: modafinil 400 mg/day
Study NCT00129285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400 mg/day
Study NCT02848092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCAL+
Description: Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
Study NCT02848092 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rules of The road
Description: Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
Study NCT04709003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic test
Description: A blood test to check antibodies type and amount
Study NCT00937131 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Rituximab
Description: Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
Study NCT03021369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural drainage system
Description: Pleural drainage system is connected to the chest tubes after surgery.
Study NCT04709003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory swabs
Description: PCR test to Covid-19
Study NCT04145076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.
Study NCT04145076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.
Study NCT04145076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
Study NCT06268002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sweetener
Study NCT01962896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01962896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT03781869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride; etoposide and cisplatin
Description: etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
Study NCT02452073 — intervention group
Intervention type: OTHER
Intervention: Thyroid function tests
Study NCT02586142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
Study NCT03848572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repetitive assessment of PRECISE-DAPT score
Description: The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
Study NCT03014375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA-5-453
Description: Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
Study NCT03224858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUMMIT intervention
Description: See description in experimental arm.
Study NCT03224858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: See description in active comparator arm.
Study NCT02586142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
Study NCT01072721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elastometry
Description: Fibrosis detection with FIBROSCANN
Study NCT00420381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until progressive disease
Study NCT00618007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 30 mg QD
Description: 30 mg QD
Study NCT00618007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 20 mg QD
Description: 20 mg QD
Study NCT00618007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01516632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS USA
Description: Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
Study NCT02479880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir DF
Description: 300 mg tablet administered orally once daily for up to 96 weeks
Study NCT02479880 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA Scan
Description: Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
Study NCT02586142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
Study NCT02431546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant.
Study NCT00355368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: 1mg/kg iv
Study NCT00355368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6mg/kg iv
Study NCT01436110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50mcg
Description: Once daily inhalation powder via Novel Dry Powder Inhaler
Study NCT01436110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: Twice daily inhalation powder via DISKUS/ACCUHALER
Study NCT01436110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
Study NCT01141127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Comparison of two dosage regimen of Tranexamic Acid
Study NCT01141127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Comparison of two dosage regimen of Tranexamic Acid
Study NCT03781869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide and cisplatin
Description: etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
Study NCT04013204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endothelial function guided therapy
Description: To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
Study NCT00833794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once a day
Study NCT00833794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03072992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
Study NCT03039738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Sync IM & VPMP (Surveillance Monitoring)
Description: The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
Study NCT03039738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry Monitoring
Description: Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
Study NCT03713879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic stenting
Description: a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)
Study NCT03287869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole tablets
Study NCT00647257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Study NCT03713879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: rectally administered indomethacin before or after ERCP
Study NCT04162132 — intervention group
Intervention type: DEVICE
Intervention: Smartphone app
Description: Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
Study NCT03453671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will use mindfulness techniques while exercising
Study NCT03453671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Participants will distract themselves while exercising
Study NCT03453671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Participants will use associative attentional focus while exercising
Study NCT00647257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Study NCT00415519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study NCT00415519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-186
Description: Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study NCT03327519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
Study NCT03327519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emmi
Description: The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
Study NCT03958539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed insoles for normal footware
Description: Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan.
Study NCT04087603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekend Morning Bright Light & Early Bedtime
Study NCT02398084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of nuts
Description: The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
Study NCT03255265 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study NCT00613717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid + iron prenatally, vits A & D + iron postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.
Study NCT00613717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid + iron prenatally, vitamins A & D postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.
Study NCT00613717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid prenatally, vitamins A & D + iron postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.
Study NCT00613717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid prenatally, vitamins A & D postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.
Study NCT01899586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Specific Training Stimulus (RSTS)
Description: The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
Study NCT01899586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Regimen (AE)
Description: Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
Study NCT02271009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AllerT
Description: Ultrafast immunotherapy
Study NCT02271009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control
Study NCT03072992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
Study NCT03072992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.